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Previous studies have shown that degeneration of retinal capillaries occurs following N-methyl-D-
aspartate (NMDA)-induced retinal neurotoxicity, but it is unclear whether vasodilatory mechanisms are
altered in retinal blood vessels. The purpose of the present study was to determine whether retinal
vasodilator responses are affected in a rat model of NMDA-induced retinal damage. At 14 days after a
single intravitreal injection of NMDA (200 nmol), retinal vasodilator responses were assessed by
measuring the diameter of retinal arterioles in fundus images. Acetylcholine-induced vasodilation of
retinal arterioles was signiﬁcantly reduced in NMDA-treated retinas, whereas retinal vasodilatory effects
of the nitric oxide (NO) donor NOR3, the b2-adrenoceptor agonist salbutamol, and the b3-adrenoceptor
agonist CL316243 were unaltered. The vasodilator response to acetylcholine observed under the com-
bined blockade of NO synthase and cyclooxygenase with NG-nitro-L-arginine methyl ester (30 mg/kg, i.v.)
plus indomethacin (5 mg/kg, i.v.), possibly an endothelium-derived hyperpolarizing factor-mediated
response, was also reduced. These results suggest that endothelium-dependent vasodilatory mecha-
nisms in retinal blood vessels are impaired in the rat model of NMDA-induced retinal degeneration.
Glutamate-induced neurotoxicity is implicated in several retinal diseases; therefore, abnormal retinal
circulation would contribute to the progression of the diseases.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Glutamate is an important excitatory neurotransmitter in the
visual system, and high concentrations of extracellular glutamate
cause neuronal cell death. Glutamate-induced neurotoxicity is
implicated in certain retinal diseases, including diabetic retinop-
athy and glaucoma (1,2). In many cases, the neurotoxic effect of
glutamate is predominantly attributed to excessive stimulation of
N-methyl-D-aspartate (NMDA) receptors (3,4).
Single intravitreal NMDA injection is commonly used to induce
retinal damage in vivo (5,6). Recent studies have demonstrated that
degeneration of retinal capillaries occurs following NMDA-induced
retinal neurotoxicity (7e9). Pathological changes in the retinal
circulation might contribute to the progression of neuronal damage
in the retina (7e10). Patients with diabetic retinopathy (11,12) and
glaucoma (13,14) frequently show a diminished ﬂicker-light-
stimulated (ﬂicker light stimulation increases neuronal activity)
increase in retinal blood ﬂow. Therefore, we hypothesized that(T. Nakahara).
acological Society.
Production and hosting by Elsevievasodilatory mechanisms in retinal blood vessels might be altered
following NMDA-induced retinal neurotoxicity.
The purpose of the present study was to determine whether
vasodilatory mechanisms are affected in retinal blood vessels in rat
models of NMDA-induced retinal damage. Our previous in vivo
studies demonstrated that acetylcholine (ACh) dilates the rat retinal
arteriole through nitric oxide (NO)- and endothelium-derived
hyperpolarizing factor (EDHF)-mediated pathways (15,16). Further-
more, presence of functional b2- and b3-adrenoceptors in the rat
retinal arteriole has been suggested (17). Therefore, we focused on
endothelium-dependent vasodilatory mechanisms and b2- and b3-
adrenoceptor-mediated vasodilation in rat retinal arterioles.2. Materials and methods
2.1. Animals
Male Wistar rats (7 weeks old) were maintained in a roomwith
constant temperature (22 ± 2 C), constant humidity (55 ± 5%), and
a 12-h light/dark cycle, and they were allowed free access to
standard rat chow and tap water. All animal procedures were per-
formed in accordance with the Association for Research in Visionr B.V. All rights reserved.
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Ophthalmic and Vision Research and the Regulations for the Care
and Use of Laboratory Animals adopted by the Institutional Animal
Care and Use Committee at Kitasato University.2.2. Reagents
The following reagents were used: ACh chloride, CL316243,
()-epinephrine (þ) bitartrate (adrenaline), ﬂuorescein sodium
salt, indomethacin, NG-nitro-L-arginine methyl ester (L-NAME), L-
()-norepinephrine (þ)-bitartrate (noradrenaline), methoxamine
hydrochloride, salbutamol hemisulfate salt (SigmaeAldrich, St.
Louis, MO, USA); NMDA, pentobarbital sodium, tetrodotoxin (TTX)
(Nacalai Tesque, Kyoto, Japan); pontamine sky blue 6B, xylazine
(Tokyo Kasei Kogyo, Tokyo, Japan); (±)-(E)-4-ethyl-2-[(E)-hydrox-
yimino]-5-nitro-3-hexenamide (NOR3) (Dojindo, Kumamoto,
Japan); and ketamine (Daiichi-Sankyo, Tokyo, Japan) and hydrox-
yethylcellulose (SCOPISOL 15®) (Senju Pharmaceutical, Osaka,
Japan). Indomethacin was dissolved in 0.24% Na2CO3. NOR3 was
dissolved in dimethyl sulfoxide (DMSO, 200 mM) and further
diluted in saline. The ﬁnal concentration of DMSO in the solution
was 0.1% and injection of this DMSO concentration did not show
any detectable effect in rats in vivo (data not shown).2.3. Experimental procedures
Intravitreal injection of NMDA was performed as previously
reported (16,18). Brieﬂy, under general anesthesia with intraperi-
toneal ketamine (90 mg/kg) and xylazine (10 mg/kg), 200 nmol
NMDA (5 mL of 40 mM NMDA in saline solution) or the same vol-
ume (5 mL) of saline was injected into the vitreous cavity of the left
eye. Injections were performed under a microscope using a 32-
gauge needle connected to a microsyringe and the needle was
inserted approximately 1 mm behind the corneal limbus.
At 14 days after intravitreal injection of NMDA or saline, vaso-
dilator responses were evaluated according to the procedures
described previously (19,20). Brieﬂy, rats were anesthetized with
pentobarbital sodium (50 mg/kg, i.p.). After disappearance of the
corneal reﬂex, each animal was placed on a heating pad. Trache-
otomy was performed for artiﬁcial ventilation. Catheters were
inserted into the femoral and jugular veins for drug administration.
The left femoral artery was cannulated tomeasure arterial pressure,
which was recorded on a thermal pen recorder (WT-645G, Nihon
Kohden, Tokyo, Japan) via a pressure transducer (DX-360, Nihon
Kohden) and a preampliﬁer (AP-610G, Nihon Kohden). Heart rate
(HR) was measured using a cardiotachometer (AT-601G, Nihon
Kohden) triggered by the blood pressure pulse. Mean arterial
pressure (MAP) and HR were digitized at 1 Hz (15BXW-H4; Dacs
Giken, Okayama, Japan) and stored on the hard disk of a personal
computer. To minimize the inﬂuence of nerve activity and capture
fundus images at the same angle throughout experimentation by
preventing eye movements, the rats were treated with TTX (50 mg/
kg, i.v.) under artiﬁcial ventilation with room air (stroke volume of
10 mL/kg; frequency of 80 strokes/min) using a rodent respirator
(SN-480-7, Shinano, Tokyo, Japan). Both MAP and HR decreased
after treatment with TTX; therefore, a 9:1 mixture solution of
adrenaline and noradrenaline was continuously injected into the
jugular vein at a constant rate by using a syringe pump (Model
1140-001, Harvard Apparatus, South Natick, MA, USA) to maintain
adequate systemic circulation (19,20). To evaluate the effects of b-
adrenoceptor agonists (salbutamol and CL316243) in experiments,
methoxamine was used because their effects might be masked by
the b-adrenoceptor agonistic actions of adrenaline and
noradrenaline.ACh (1e10 mg/kg/min), NOR3 (3e30 mg/kg/min), salbutamol
(0.1e1 mg/kg/min, i.v.), or CL316243 (0.3e3 mg/kg/min, i.v.) was
infused into the femoral vein by using a syringe pump (Model 1140-
001, Harvard Apparatus), and the infusion rate was increased in a
stepwise fashion. Doses of ACh and salbutamol that have no sig-
niﬁcant effect on HR were chosen on the basis of our previous
studies (15,17,21,22).
We also determined whether the vasodilator responses to ACh
observed under inhibition of NO synthase and cyclooxygenase,
EDHF-mediated vasodilation, is affected in NMDA-treated retinas.
In this set of experiments, rats were treated with L-NAME (30 mg/
kg, i.v.) and indomethacin (5 mg/kg, i.v.) just before starting infu-
sion of a mixture solution of adrenaline and noradrenaline
(~20 min before starting the infusion of ACh). Doses of L-NAME and
indomethacin were chosen based on the results of previous studies
(15,18,23).
At the end of the experiments, the rats were sacriﬁced and their
eyes were enucleated and immersed for 12 h in a ﬁxative mixture
(37.5% ethanol, 9.3% formaldehyde, 12.5% acetic acid, and 3%
glutaraldehyde) at room temperature as reported previously (22,24).
Fixed retinal tissueswere embedded in parafﬁn, and 5 mmhorizontal
sections through the optic disc of the eye were cut. Sections were
stained with hematoxylin and eosin, and a histological analysis was
performed to conﬁrm NMDA-induced retinal damage.2.4. Fundus photography and retinal arteriolar diameter
measurement
The techniques used for fundus photography and retinal arte-
riolar diameter measurement were previously described (20,23).
Brieﬂy, hydroxyethylcellulose (SCOPISOL 15®) was dropped onto
the cornea of rats to prevent drying of the eye. The optic disc was
centered and focused in the ﬁeld of view. Sodium ﬂuorescein (10%
solution, 0.8 mL/kg) and pontamine sky blue 6B (5% solution,
0.8 mL/kg) were injected into the right femoral vein to enhance
blood vessel contrast. Fundus images were captured using a digital
camera (EOS7D; Canon, Tokyo, Japan) equipped with a bore scope-
type objective lens for small animals (Model 01; Scalar, Tokyo,
Japan) and stored on the hard disk of a laboratory computer. A
region (120  240 mm) of fundus image (3456  5184 mm) con-
taining a retinal arteriole was selected for analysis, and the diam-
eter of the vessel in the same region was measured throughout the
experiment.2.5. Data analyses
The diameter of the retinal arteriole, MAP, and HR were
expressed as percentages of baseline values obtained (mean values
of data obtained at the time from 2 min to 0 min) just before the
infusion of test drugs. An unpaired t-test was used to compare
baseline values of control and NMDA-treated groups. A two-way
analysis of variance (Two-way ANOVA) was used to compare re-
sponses between groups. A P value less than 0.05 was considered
statistically signiﬁcant. All values are presented as the mean ± S.E.M.3. Results
We conﬁrmed morphological changes in the overall retinal ar-
chitecture in parafﬁn sections 14 days after intravitreal injection of
NMDA (Supplementary Fig. 1). Compared to the control retinas,
NMDA-treated retinas showed fewer cells in the ganglion cell layer
and reduced thickness of the inner plexiform layer. These histolog-
ical changes are consistent with those reported previously (9,24).
Fig. 1. Changes in retinal arteriolar diameter (AD, A), mean arterial pressure (MAP, B)
and heart rate (HR, C) induced by intravenous infusion of acetylcholine (1e10 mg/kg/
min) in rats treated with intravitreal injection of saline (Control, n ¼ 9) or NMDA
(n ¼ 10). Data are expressed as percentage of the control level (baseline values
measured before infusion of acetylcholine). Each point with a vertical bar represents
mean ± S.E.M. *P < 0.05 vs. control (saline-treated) group.
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retinal arteriolar diameter, MAP, or HR between the saline- and
NMDA-treated groups (Table 1).
ACh (1e10 mg/kg/min, i.v.) dilated retinal arterioles and
decreased MAP in a dose-dependent manner (Fig. 1A and B) in both
saline- and NMDA-treated rats. The doses of ACh used in this study
did not signiﬁcantly alter HR in either group (Fig. 1C). ACh-induced
retinal vasodilator responses, but not depressor responses, in
NMDA-treated rats were smaller than those in control rats.
Our previous studies demonstrated that the NO synthase in-
hibitor L-NAME signiﬁcantly attenuates the retinal arteriolar dila-
tion and the depressor response to ACh (15,16). Thus, ACh seems to
elicit vasodilator effects on retinal and peripheral arterioles
through activation of NO synthase. Therefore, we next examined
whether vasodilation induced by the NO donor NOR3 is affected in
NMDA-treated retinas. NOR3 (3e30 mg/kg/min, i.v.) caused dose-
dependent vasodilation of retinal arterioles and depressor re-
sponses (Fig. 2); however, both responses were unaffected in
NMDA-treated retinas (Fig. 2).
Our previous studies also demonstrated that ACh dilates the rat
retinal arteriole partly through NO- and prostaglandin-
independent pathways, possibly the EDHF-mediated pathway
(15,16). Therefore, we next examined whether the EDHF-mediated
vasodilation is affected in NMDA-treated retinas. Vasodilator re-
sponses to ACh observed under treatment with L-NAME and
indomethacin were signiﬁcantly attenuated in NMDA-treated
retina (Fig. 3A), whereas depressor responses to ACh were unaf-
fected (Fig. 3B).
Lastly, we determined whether b-adrenoceptor-mediated
vasodilation is affected in NMDA-treated retinas. As shown in Fig. 4,
salbutamol (0.1e1 mg/kg/min, i.v.) induced the vasodilation of
retinal arterioles and the depressor response in a dose-dependent
manner without affecting HR. There were no signiﬁcant differ-
ences between saline- and NMDA-treated groups. Similarly, the b3-
adrenoceptor agonist CL316243 (0.3e3 mg/kg/min, i.v.) caused
retinal vasodilator and depressor responses in a dose-dependent
manner (Fig. 5). These CL316243-induced responses were not
signiﬁcantly different between groups.4. Discussion
The present study demonstrates that retinal arteriolar responses
to ACh, but not NOR3, salbutamol, or CL316243, are diminished in
NMDA-treated retinas. ACh-induced vasodilation of retinal arteri-
oles under co-treatment with L-NAME and indomethacin, whichTable 1
Baseline values of retinal arteriolar diameter (AD), mean arterial pressure (MAP),
and heart rate (HR) in each experimental group.
Experimental groups AD (mm) MAP (mmHg) HR (beats/min)
Studies for acetylcholine and NOR3
Control (n ¼ 14) 53.5 ± 1.7 105 ± 2 496 ± 7
NMDA (n ¼ 15) 52.1 ± 1.8 104 ± 2 495 ± 6
Studies for acetylcholine under treatment with L-NAME and indomethacin
Control (n ¼ 8) 44.9 ± 1.9 122 ± 8 406 ± 21
NMDA (n ¼ 6) 46.5 ± 1.7 120 ± 7 404 ± 10
Studies for salbutamol and CL316243
Control (n ¼ 10) 50.5 ± 1.3 112 ± 3 328 ± 5
NMDA (n ¼ 11) 50.2 ± 2.6 109 ± 2 331 ± 5
Values represent the mean ± S.E.M. During the experiments, a 9:1 mixture solution
of adrenaline and noradrenaline was continuously infused, but methoxamine was
infused in experiments designed to evaluate the effects of salbutamol and
CL316243. These values were measured just before starting the infusion of each
vasodilator.
Fig. 2. Changes in retinal arteriolar diameter (AD, A), mean arterial pressure (MAP, B)
and heart rate (HR, C) induced by intravenous infusion of NOR3 (3e30 mg/kg/min) in
rats treated with intravitreal injection of saline (Control, n ¼ 5) or NMDA (n ¼ 5). Data
are expressed as percentage of the control level (baseline values measured before
infusion of NOR3). Each point with a vertical bar represents mean ± S.E.M.
Fig. 3. Changes in retinal arteriolar diameter (AD, A), mean arterial pressure (MAP, B)
and heart rate (HR, C) induced by intravenous infusion of acetylcholine (1e10 mg/kg/
min) under treatment with NG-nitro-L-arginine methyl ester (L-NAME; 30 mg/kg, i.v.)
and indomethacin (5 mg/kg, i.v.) in rats treated with intravitreal injection of saline
(Control, n ¼ 8) or NMDA (n ¼ 6). Data are expressed as percentage of the control level
(baseline values measured before infusion of acetylcholine). Each point with a vertical
bar represents mean ± S.E.M. *P < 0.05 vs. (saline-treated) group.
Fig. 5. Changes in retinal arteriolar diameter (AD, A), mean arterial pressure (MAP, B)
and heart rate (HR, C) induced by intravenous infusion of CL316243 (0.3e3 mg/kg/min)
in rats treated with intravitreal injection of saline (Control, n ¼ 5) or NMDA (n ¼ 5).
Data are expressed as percentage of the control level (baseline values measured before
infusion of CL316243). Each point with a vertical bar represents mean ± S.E.M.
Fig. 4. Changes in retinal arteriolar diameter (AD, A), mean arterial pressure (MAP, B)
and heart rate (HR, C) induced by intravenous infusion of salbutamol (0.1e1 mg/kg/
min) in rats treated with intravitreal injection of saline (Control, n ¼ 5) or NMDA
(n ¼ 6). Data are expressed as percentage of the control level (baseline values
measured before infusion of salbutamol). Each point with a vertical bar represents
mean ± S.E.M.
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EDHF, was reduced in NMDA-treated retinas. These results suggest
that in the retinal arterioles of NMDA-treated rats, the production
of and/or vascular responsiveness to EDHF are impaired, whereas
the vascular responses induced by exogenously administered NO
and stimulation of b2/b3-adrenoceptors are unaltered.
Our previous studies demonstrated that retinal vasodilator
responses to ACh and b2-adrenoceptor agonists were markedly
diminished in diabetic rat retina, but the vascular function of b3-
adrenoceptors was preserved (15,17,21,25). The retinal vasodilator
responses to ACh are mediated through both NO-dependent and
NO-independent mechanisms (15,25). The NO- and
prostaglandin-independent, possibly EDHF-mediated, rather than
the NO-dependent, component of the retinal vasodilator
response to ACh was attenuated in diabetic rats (15,21). Thus,
retinal vasodilatory mechanisms involving EDHF and b2-adreno-
ceptors seem to be more vulnerable to the effects of hypergly-
cemia than those involving b3-adrenoceptors. On the other hand,
in models of NMDA-induced retinal neuronal damage, such high
susceptibility of the b2-adrenoceptor system was not observed,
although the EDHF-mediated pathway was impaired. Endothelial
cells might exhibit greater susceptibility to neuronal damage
than vascular smooth muscles, but clear differences were seen
between the effects of hyperglycemia and neurotoxicity on
retinal arterioles.
At present, the mechanisms of EDHF-mediated responses in rat
retinal arterioles are not fully understood. However, our previous
results suggested that activation of large-conductance Ca2þ-acti-
vated Kþ (BKCa) channels contributes to the EDHF-mediated
component of vasodilator response to ACh of rat retinal arterioles
but small and intermediate Ca2þ-activated Kþ channels play minor
roles in the response (16). Therefore, it will be interesting to
A. Mori et al. / Journal of Pharmacological Sciences 127 (2015) 211e216 215determine whether the retinal vasodilatory mechanism involving
the activation of BKCa channels is impaired in NMDA-treated retinas
in future studies.
The mechanisms underlying vascular endothelial cell damage in
NMDA-treated retinas remain to be elucidated, but at least three
mechanisms are proposed. First, damage to neuronal cells could be
a mechanism for vascular abnormalities in the rat retina. Results
from a time-course study suggest that neurodegenerative events
precede vascular damage in NMDA-treated retinas (9). NMDA re-
ceptors have been identiﬁed on retinal ganglion and amacrine cells,
whereas endothelial and vascular smooth muscle cells probably do
not express NMDA receptors (26). Therefore, direct effects of NMDA
on retinal blood vessels are unlikely. In the NMDA-induced retinal
degeneration model, changes in the retinal layer were limited in
the inner retina, as demonstrated by the loss of retinal ganglion
cells and thinning of the inner plexiform layer. Neuronal cells in the
inner retina may play a role in maintaining the structure and
function of retinal blood vessels through the production and/or
release of growth factors and trophic factors for vascular cells. For
example, retinal ganglion cells express vascular endothelial growth
factor (VEGF) in the rat retina (27). Consequently, a loss of retinal
ganglion cells in the retina may fail to provide sufﬁcient amounts of
VEGF for maintaining vascular function. Second, previous studies
suggest that NO produced by inducible NO synthase and oxidative
stress may be involved in retinal vascular damage (10,28). There-
fore, excessive production of NO and oxidative stress may also
contribute to the vascular damage seen in the NMDA-treated retina.
Finally, leukocyte rolling and accumulation in retinal vessels have
been observed in models of NMDA-induced retinal degeneration
(29). The substances released from leukocytes may be toxic for both
vascular and neuronal cells.5. Conclusions
The present study clearly demonstrates that retinal blood ves-
sels are damaged functionally in a rat model of NMDA-induced
retinal degeneration. Glutamate-induced excitotoxicity contrib-
utes to several retinal diseases, including retinal ischemia, diabetic
retinopathy, and glaucoma (1,2). In such diseases, neuronal cell
injury may reduce blood supply to retinal neurons and result in
progressive retinal damage. Therefore, one strategy to prevent the
progression of these retinal diseases is to protect endothelial cells
in retinal blood vessels. Agents that effectively dilate blood vessels
in damaged retinas may be candidate therapeutics for such retinal
diseases because of their ability to improve retinal circulation. In
contrast to NO donors and b2-adrenoceptor agonists, stimulation of
b3-adrenoceptors produced minor systemic cardiovascular effects.
This favorable characteristic suggests that b3-adrenoceptor agonists
may serve as promising therapeutic candidates for improving
impaired retinal circulation.Conﬂict of Interest
All authors declare no conﬂict of interest.Acknowledgments
This study was supported by Kitasato University Research Grant
for Young Researchers (A.M.), Kao Foundation for Arts and Sciences
(A.M.), JSPS KAKENHI (Grant Numbers: 22790260 A.M., 24790261
A.M. and 24590122 K.I.), and MEXT KAKENHI (Grant Numbers:
23122517 T.N., 25122712, T.N.).Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.jphs.2014.12.014.References
(1) Casson RJ. Possible role of excitotoxicity in the pathogenesis of glaucoma. Clin
Experiment Ophthalmol. 2006;34:54e63.
(2) Hernandez C, Simo R. Neuroprotection in diabetic retinopathy. Curr Diab Rep.
2012;12:329e337.
(3) Lam TT, Siew E, Chu R, Tso MO. Ameliorative effect of MK-801 on retinal
ischemia. J Ocul Pharmacol Ther. 1997;13:129e137.
(4) Solberg Y, Rosner M, Turetz J, Belkin M. MK-801 has neuroprotective and
antiproliferative effects in retinal laser injury. Invest Ophthalmol Vis Sci.
1997;38:1380e1389.
(5) Siliprandi R, Canella R, Carmignoto G, Schiavo N, Zanellato A, Zanoni R, et al.
N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina. Vis
Neurosci. 1992;8:567e573.
(6) Lam TT, Abler AS, Kwong JM, Tso MO. N-methyl-D-aspartate (NMDA)e
induced apoptosis in rat retina. Invest Ophthalmol Vis Sci. 1999;40:
2391e2397.
(7) Al-Gayyar MM, Abdelsaid MA, Matragoon S, Pillai BA, El-Remessy AB. Neu-
rovascular protective effect of FeTPPs in N-methyl-D-aspartate model: simi-
larities to diabetes. Am J Pathol. 2010;177:1187e1197.
(8) Ueda K, Nakahara T, Hoshino M, Mori A, Sakamoto K, Ishii K. Retinal blood
vessels are damaged in a rat model of NMDA-induced retinal degeneration.
Neurosci Lett. 2010;485:55e59.
(9) Ueda K, Nakahara T, Mori A, Sakamoto K, Ishii K. Protective effects of TGF-b
inhibitors in a rat model of NMDA-induced retinal degeneration. Eur J Phar-
macol. 2013;699:188e193.
(10) Zheng L, Gong B, Hatala DA, Kern TS. Retinal ischemia and reperfusion causes
capillary degeneration: similarities to diabetes. Invest Ophthalmol Vis Sci.
2007;48:361e367.
(11) Garh€ofer G, Zawinka C, Resch H, Kothy P, Schmetterer L, Dorner GT. Reduced
response of retinal vessel diameters to ﬂicker stimulation in patients with
diabetes. Br J Ophthalmol. 2004;88:887e891.
(12) Nguyen TT, Kawasaki R, Wang JJ, Kreis AJ, Shaw J, Vilser W, et al. Flicker light-
induced retinal vasodilation in diabetes and diabetic retinopathy. Diabetes
Care. 2009;32:2075e2080.
(13) Garh€ofer G, Zawinka C, Resch H, Huemer KH, Schmetterer L, Dorner GT.
Response of retinal vessel diameters to ﬂicker stimulation in patients with
early open angle glaucoma. J Glaucoma. 2004;13:340e344.
(14) Gugleta K, Kochkorov A, Waldmann N, Polunina A, Katamay R, Flammer J,
et al. Dynamics of retinal vessel response to ﬂicker light in glaucoma pa-
tients and ocular hypertensives. Graefe’s Arch Clin Exp Ophthalmol.
2012;250:589e594.
(15) Nakazawa T, Kaneko Y, Mori A, Saito M, Sakamoto K, Nakahara T, et al.
Attenuation of nitric oxide- and prostaglandin-independent vasodilation of
retinal arterioles induced by acetylcholine in sterptozotocin-treated rats. Vasc
Pharmacol. 2007;46:153e159.
(16) Mori A, Suzuki S, Sakamoto K, Nakahara T, Ishii K. Role of calcium-activated
potassium channels in acetylcholine-induced vasodilation of rat retinal arte-
rioles in vivo. Schmiedeb Arch Pharmacol. 2011;383:27e34.
(17) Mori A, Miwa T, Sakamoto K, Nakahara T, Ishii K. Pharmacological evidence for
the presence of functional beta3-adrenoceptors in rat retinal blood vessels.
Schmiedeb Arch Pharmacol. 2010;382:119e126.
(18) Ogawa N, Mori A, Hasebe M, Hoshino M, Saito M, Sakamoto K, et al. Nitric
oxide dilates rat retinal blood vessels by cyclooxygenase-dependent
mechanisms. Am J Physiol Regul Integr Comp Physiol. 2009;297:
R968eR977.
(19) Kaneko Y, Saito M, Mori A, Sakamoto K, Nakahara T, Ishii K. Vasodilator effects
of adrenomedullin on retinal arterioles in streptozotocin-induced diabetic
rats. J Ocul Pharmacol Ther. 2006;22:317e322.
(20) Mori A, Saito M, Sakamoto K, Narita M, Nakahara T, Ishii K. Stimulation of
prostanoid IP and EP2 receptors dilates retinal arterioles and increases
retinal and choroidal blood ﬂow in rats. Eur J Pharmacol. 2007;570:
135e141.
(21) Nakazawa T, Mori A, Saito M, Sakamoto K, Nakahara T, Ishii K. Vasodilator
effects of adenosine on retinal arterioles in streptozotocin-induced diabetic
rats. Schmiedeb Arch Pharmacol. 2008;376:423e430.
(22) Mori A, Saigo O, Hanada M, Nakahara T, Ishii K. Hyperglycemia accelerates
impairment of vasodilatior responses to acetylcholine of retinal blood vessels
in rats. J Pharm Sci. 2009;110:160e168.
(23) Ogawa N, Saito M, Mori A, Sakamoto K, Kametaka S, Nakahara T, et al.
Vasodilator effect of nicorandil on retinal blood vessels in rats. Schmiedeb
Arch Pharmacol. 2007;375:323e328.
(24) Mori A, Ishii T, Kuroki T, Shigeta N, Sakamoto K, Nakahara T, et al. The
prostanoid EP2 receptor agonist ONO-AE1-259-01 protects against
glutamate-induced neurotoxicity in rat retina. Eur J Pharmacol. 2009;616:
64e67.
A. Mori et al. / Journal of Pharmacological Sciences 127 (2015) 211e216216(25) Mori A, Suzuki S, Sakamoto K, Nakahara T, Ishii K. Vasodilation of retinal ar-
terioles induced by activation of BKCa channels is attenuated in diabetic rats.
Eur J Pharmacol. 2011;669:94e99.
(26) Ng YK, Zeng XX, Ling EA. Expression of glutamate receptors and calcium-
binding proteins in the retina of streptozotocin-induced diabetic rats. Brain
Res. 2004;1018:66e72.
(27) Ogata N, Yamanaka R, Yamamoto C, Miyashiro M, Kimoto T, Takahashi K, et al.
Expression of vascular endothelial growth factor and its receptor, KDR,following retinal ischemia-reperfusion injury in the rat. Curr Eye Res.
1998;17:1087e1096.
(28) Chen B, Caballero S, Seo S, Grant MB, Lewin AS. Delivery of antioxidant
enzyme genes to protect against ischemia/reperfusion-induced injury to
retinal microvasculature. Invest Ophthalmol Vis Sci. 2009;50:5587e5595.
(29) Nakazawa T, Takahashi H, Nishijima K, Shimura M, Fuse N, Tamai M, et al.
Pitavastatin prevents NMDA-induced retinal ganglion cell death by sup-
pressing leukocyte recruitment. J Neurochem. 2007;100:1018e1031.
